

# EPA's ToxCast Program: From Research to Application

*David Dix*  
*National Center for Computational Toxicology*

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY



OECD Molecular Screening  
26 Oct 2009  
Paris, France


Office of Research and Development  
National Center for Computational Toxicology

26 Oct 2009






*This work was reviewed by EPA and approved for publication but does not necessarily reflect official Agency policy.*

# ToxCast™ Background


- Research program of EPA's National Center for Computational Toxicology
- Addresses chemical screening and prioritization needs for pesticidal inerts, antimicrobials, CCLs, HPVs and MPVs
- Comprehensive use of HTS technologies
- Coordinated with NTP and NHGRI/NCGC via Tox21
- Committed to stakeholder involvement and public release of data
  - Chemical Prioritization Community of Practice
  - NCCT website- <http://www.epa.gov/ncct/>



# HTS in Drug Development




# HTS in Toxicology




# EPA's Need for Prioritization

## Too Many Chemicals



IRIS      TRI      Pesticides  
 Inerts      CCL 1 & 2      HPV  
 MPV

## Too Little Data (%)



Acute      Cancer      Gentox  
 Dev Tox      Repro Tox

# Chemical Prioritization

## Pesticides: Current Status

- Antimicrobials (300 Total)
  - ~100 have undergone (re-)registration since 1996 (FQPA)
  - Limited to no toxicity information
  - Limited regulatory capacity for requesting toxicity data
  - Current practice:
    - *Food-use to non-food-use chemicals*
    - *Chemical groupings by structure similarity*
  - Potential need:
    - *Biologically-based support for toxicity data requests*
    - *Re-registration prioritization*
    - *Biologically driven chemical groupings*
- Inerts ('Other' Ingredients (>4500 Total))
  - Legislative mandate to (re)assess all 'other' ingredients
  - ~700 Currently re-assessed (~2500 previously assessed)
  - Limited to no toxicity information
  - Limited to no regulatory capacity for requesting toxicity data
  - Current practice:
    - *Limited use of QSAR models*
    - *Use limited available information in categorical assessment*
    - *Tackle recognizably safe chemicals 1<sup>st</sup> (GRAS, etc.)*
  - Potential need:
    - *Prioritization & Classification of Ingredients*
    - *Biologically driven chemical groupings*
    - *Targeted testing of chemicals/groups*

# Chemical Prioritization

## Industrial: Current Status


- HPV (~3500 Total)
  - >1 Million lbs production/importation
  - 2200 Part of HPV Challenge
  - Wide range of toxicological data availability
  - Limited to no regulatory capacity for requesting toxicity data
  - Current practice:
    - HPV Categories (Chemical groupings by structural similarity)
    - Use of QSAR models
  - Potential need:
    - Biologically driven chemical groupings
    - Rapid evaluation of chemicals with no toxicity information
- MPV (~2800)
  - >25,000 lbs production/importation
  - Wide range of toxicological data availability (primarily SIDS)
  - ChAMP expanded to MPVs
  - Current practice:
    - Hazard-based (screening-level documents)
    - Consider QSAR estimates
    - Consider Canada's categorization results
  - Potential need:
    - Enhance use of models with screening data
    - Rapid evaluation of chemicals with no toxicity information



# ToxCast\_320

## 309 Unique Chemicals

- 3 Triplicates
- 5 Duplicates
- 276 Conventional Actives
- 16 Antimicrobials
- 9 Industrial Chemicals
- 8 Metabolites
- 75 Chemical Classes



Chemical Class Distribution  
(≥5/Class)

Organophosphorus (39)	Dinitroaniline (7)
Amide (26)	Antibiotic (7)
Urea (26)	Thiocarbamate (7)
Conazole (18)	Pyrazole (6)
Carbamate (16)	Nicotinoid (6)
Phenoxy (15)	Dithiocarbamate (6)
Pyrethroid (12)	Aromatic Acid (6)
Pyridine (11)	Insect Growth Regulators (5)
Triazine (9)	Imidazolinone (5)
Dicarboximide (8)	Unclassified (21)
Phthalate (7)	Other (93)



# ToxCast Assays

## Biochemical Assays

- Protein families
  - GPCR
  - NR
  - Kinase
  - Phosphatase
  - Protease
  - Other enzyme
  - Ion channel
  - Transporter
- Assay formats
  - Radioligand binding
  - Enzyme activity
  - Co-activator recruitment

**467 Total  
Endpoints**

## Cellular Assays

- Cell lines
  - HepG2 human hepatoblastoma
  - A549 human lung carcinoma
  - HEK 293 human embryonic kidney
- Primary cells
  - Human endothelial cells
  - Human monocytes
  - Human keratinocytes
  - Human fibroblasts
  - Human proximal tubule kidney cells
  - Human small airway epithelial cells
- Biotransformation competent cells
  - Primary rat hepatocytes
  - Primary human hepatocytes
- Assay formats
  - Cytotoxicity
  - Reporter gene
  - Gene expression
  - Biomarker production
  - High-content imaging for cellular phenotype

# ToxCast: Pathway Coverage


● Biologically Multiplexed  
Activity Profiling (BioMAP)

● Multiplex Transcription  
Reporter Assay


● Cell-based HTS Assays

● Cell-free HTS Assays

● High Content Cell Imaging  
Assays



# Multiple Assays & Technologies Per Target




## Some Expected Results...


- Estrogen receptor (ER)
  - Bisphenol A, Methoxychlor, HPTE
- Androgen Receptor (AR)
  - Vinclozolin, Linuron, Prochloraz
- PPAR
  - PFOA, PFOS, Diethylhexyl Phthalate, Lactofen
- Mitochondrial Poisons
  - Azoxystrobin, Fluoxastrobin, Pyraclostrobin
- Acetylcholinesterase Inhibition
  - Multiple organophosphorus pesticides

# What is a hit?

ERE\_CIS




ERa\_TRANS



# ToxCast Phase I Assay Hits (n=624 measurements)

Novascreen (Knudsen et al, NCB, submitted)	Cell Free HTS
Attagene (Martin et al, CRT, submitted)	Multiplexed TF
Bioseek (Houck et al, JBS, published)	Human BioMap
Cellumen (Houck et al, In prep)	HCS
CellzDirect (Rotroff et al, TAP, submitted)	qNPAs
Solidus (Ryan et al, In prep)	Cytotox/XMEs
ACEA (Judson et al, In prep)	Impedance
Gentronix (Knight et al, RTP, published)	Genotoxicity

**828 Assay-Chemical Pairs  
had AC50s of less than 1 $\mu$ M**



# ToxRefDB

- Relational phenotypic/toxicity database
  - Stores Guideline In Vivo Laboratory Animal Toxicology Data
  - All Treatment-Related Effects at All Dose Levels Captured
- Provides in vivo anchor for ToxCast predictions
- Focus: 3 study types
  - Chronic/Cancer Rat and Mouse (Martin, et al, EHP 2008)
  - Rat Multigeneration Reproductive Toxicity (Martin, et al, ToxSci 2009)
  - Rat & Rabbit Developmental Toxicity (Knudsen, et al, ReproTox 2009)
- Two types of synthesis
  - Supervised (common individual phenotypes)
  - Unsupervised (machine based clustering of phenotype patterns)





**ToxRefDB**

[illegible]

Knudsen et al. (2009) *Reprod Toxicol*  
doi: 10.1016/j.reprotox.2009.03.016



# ToxRefDB in Predictive Modeling


## STRENGTHS

- Source data from >2,000 guideline studies
- Puts >\$2B worth of legacy data into a computable form
- *in vivo* database anchoring HTS *in vitro* assays
- Enables comparison of endpoint incidence between species
- Searchable database will be public ([www.epa.gov/ncct/toxrefdb/](http://www.epa.gov/ncct/toxrefdb/))


## LIMITATIONS

- Endpoints aggregated as independent features
- Data largely qualitative (LELs, LOAELS)
- Not all ToxCast™ chemicals represented in ToxRefDB
- Not all ToxRefDB chemicals represented in ToxCast™
- Species dimorphism may link to biology or study design
- Limited mode of action information available in source DERs
- Not all endpoints routinely measured/captured


# Rat Liver Histopathology from Chronic Bioassays



# Predicting Toxicity Is Not Easy




# Rat Liver Tumor Correlations



		AR	PPARA	PPARG	HMGCS2	CCL2
Malathion						
Mevinphos						
Ametryn						
Simazine						
Acetochlor						
Dimethenamid						
Vinclozolin						
Cyclanilide						
Dichlobenil						
Fludioxonil						
Imazail						
2,5-Pyridinedicarboxylic acid, dipropyl ester						
Pyrimetozine						
Tebufenpyrad						
Isoxaflutole						
Lactofen						
Diclofop-methyl						
Oxadiazon						
Diethylhexyl phthalate						
Carbaryl						
Tepraloxymim						

# Gene Networks Associated with Progression of Rat Liver Tumor Endpoints



# Some Challenges Faced or to be Faced


- **Quality control of the chemical library**
  - Acceptable purity, stability, and organization
- **Defining/normalizing conc. response ranges**
- **Definition/Calculation of a hit**
  - Minimum fold change; minimum r-squared; limit on Hill function
- **Interpretation of hits and causality**
  - Statistical vs. biological relevance
  - Association vs. causation
- **Assay performance**
  - Replicates, artifacts
- **Sufficient coverage of biological pathways**
  - Including those that represent tissue level processes
- **Incorporation of metabolic competency**
- **Establishment of target prediction**
  - Pathway perturbation
  - Rodent bioassay data
  - Rodent mechanistic studies
  - Human effects
- **Sufficient representation of positives to predict against**



# Potential Application to Chemical Programs: Endocrine Profiling & Prioritization


## EDSP (Currently 67)

- 53 in ToxCast\_320
- Tiered testing program
- Regulatory capacity to request data under FFDCA
- Mandate to test all chemicals
- Current practice:
  - *Exposure based chemical selection*
  - *Not selected based on potential endocrine disruption*
  - *Two-tier system*
- Potential need:
  - *Pre-screen for ER, AR, or TR activity*
  - *Priority setting/targeted testing once expanded to evaluating all chemicals*




Each chemical signature/ gives a priority score (ToxScore) that can be ranked along any domain

$$\text{ToxScore} = f(\text{In vitro assays} + \text{Chemical properties} + \text{Pathways} + \text{In vivo endpoints})$$




# ToxCast Hazard-Based Prioritization

$$\text{ToxScore} = f(\text{Chemical properties} + \text{In vitro assays} + \text{Pathways} + \text{Dosimetry})$$



$$\text{ToxScore} = \sum_1^C w_c * \text{chemProp}_c + \sum_1^I w_i * \text{assay}_i + \sum_1^P w_p * \text{pathway}_p + \sum_1^E w_e * \text{dosimetry}_e$$

Example ToxScores prioritizing chemicals for Cancer, Systemic, Reproductive or Developmental testing, respectively.



# Prioritization Product Timeline

Phase	Number of Chemicals	Chemical Criteria	Purpose	Number of Assays	Cost per Chemical	Target Date
Ia	320	Data Rich (pesticides)	Signature Development	552	\$20k	FY07-09
Ib	15	Nanomaterials	Pilot	166	\$10K	FY09
IIa	>300	Data Rich Chemicals	Validation	>400	~\$20-25k	FY09-11
IIb	>100	Known Human Toxicants	Extrapolation	>400	~\$20-25k	FY09-11
IIc	>300	Expanded Structure and Use Diversity	Extension	>400	~\$20-25k	FY09-11
IId	>12	Nanomaterials	PMN	>200	~\$15-20K	FY10-11
III	Thousands	Data poor	Prediction and Prioritization	>300	~\$15-20k	FY11-12

FY07

FY08

FY09

FY10

FY11

FY12

Proof of Concept: ToxCast

Verification/Extension

Reduce to Practice

Tox21

# Phase II Plans

- Done in conjunction with Tox21 10k Library
  - Subset of 700 will seed Phase II
- Chemical Diversity
  - More food use active pesticides (~100-200)
  - Pesticidal antimicrobials & inerts (~100-200)
  - Failed pharmaceuticals (preclinical and clinical, ~100-150)
  - “Green” chemicals
  - HPV Categories
  - Liver toxicants
  - OECD Molecular Screening Group nominations
- Evaluation of Phase I Assays
- Additional assays via competitive procurements, collaborative partners...